LATEST ANNOUNCEMENT

Interim clinical trial results show promise in the treatment of Acute Promyelocytic Leukaemia (APL)

The interim results show promise for an oral arsenic formulation for treatment of Acute Promyelocytic Leukemia (APL) which is a subtype of acute myeloid leukemia (AML), and accounts for only 10% of all AML diagnoses.